AddedRisk Factors
equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedRisk Factors
Our reliance on these third parties for such development activities will reduce our control over these activities but will not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedRisk Factors
materials to manufacture our products and product candidates, we may experience delays in our commercialization and development efforts, which would have an adverse effect on our business and results of operations.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedRisk Factors
delay commercialization efforts of XDEMVY or any future products, if approved, clinical development of product candidates or marketing approval of current or future product candidates.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RemovedRisk Factors
CMOs and other suppliers are subject to inspection by the FDA and may receive observations that they may not be able to resolve in a timely or effective manner, which could impact whether our products can be approved on a timely basis, if at all.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
The commercialization of XDEMVY and the development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. In 2019 and 2020, we entered into the Eye and Derm Elanco Agreement and the All Human Uses Elanco Agreement, respectively. We have utilized these license rights in
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
Reauthorization Act of 2015 which first affected physician payment in 2019. It is unclear how the introduction of the Medicare quality payment program will impact our business.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
CCPA and other state laws could impact our business activities depending on how they are interpreted and exemplify the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information. The CCPA may increase our compliance costs and potential liability, and similar laws have been proposed at the federal level and have been proposed and enacted in other states.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
As of December 31, 2024, we no longer qualified as an emerging growth company or a smaller reporting company and, as a result, are no longer able to avail ourselves of certain reduced reporting requirements applicable to emerging growth companies or smaller reporting companies, subject to applicable transition relief.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
On June 28, 2024, the last business day of the second quarter of 2024, the aggregate market value of the shares of our common stock held by non-affiliate stockholders exceeded $700.0 million. As a result, we became a large accelerated filer as of December 31, 2024, as defined in Rule 12b-2 under the Exchange Act, and ceased to qualify as an emerging growth company. Effective December 31, 2024, due to large accelerated filer status, we no longer qualify as a smaller reporting company and accordingly are not permitted to take advantage of the reduced reporting requirements for smaller reporting companies, subject to a transition period that allows us to use smaller reporting company scaled disclosure for our Annual
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
Report on Form 10-K for the year ending December 31, 2024. With the transition to becoming a large accelerated filer, we did not elect to use the smaller reporting company scaled disclosures.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
As a result of our loss of emerging growth company and smaller reporting company status, we expect our operating costs to increase as our compliance, reporting and other costs increase.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RewordedRisk Factors
For example, in March 2024 2025, we completed a follow-on public offering of 3.3 approximately 3.2 million shares of our common stock at a public offering price of $32.00 $44.50 per share and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 shares of our common stock at a price of $31.9999 per pre-funded warrant, share, for aggregate net proceeds of approximately $107.7 $134.8 million (after deducting underwriting discounts, commissions and other estimated offering-related expenses) and in 2023 we raised approximately $19.2 million, after deducting broker commissions and fees, through sales under our 2023 ATM Prospectus. expenses).
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
The 2024 Credit Facility provides for We did not draw on any of the three potential additional term loan tranches in principal amounts up to of $25.0 million, $50.0 million, and $50.0 million, million respectively, subject to customary conditions to funding and, in the case each of the last two tranches, achieving minimum net sales milestones, which may be requested expired on or prior to December 31, 2024, June 30, 2025 2025, and December 31, 2025, respectively. 2025.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
While the regulatory provisions that purported to affect the applicability of the best price and average manufacturer price exclusions of manufacturer-sponsored patient benefit programs, in the context of Certain pharmacy benefit managers ("PBM") (“PBM”) “accumulator” and "maximizer" “maximizer” programs that attempted to implement these regulations were invalidated by a court, but such programs may continue to negatively affect us in other ways.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Further, the IRA established a Medicare Part D Prescription Drug Program ("Medicare Part D") inflation rebate scheme, (with with the first rebate period taking place in the fourth quarter of 2022 through the third quarter of 2023, and a drug price negotiation program, under which the prices for Medicare units of certain high Medicare spend drugs and biologics without generic or biosimilar competition will be capped by reference to, among other things, a specified Non-FAMP, with the first negotiated prices to take effect in 2026.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we, or our manufacturing partners, are unable to successfully scale up the manufacture of XDEMVY or our product candidates in sufficient quality and quantity, the commercialization of XDEMVY or the development, testing and clinical trials of that product candidate may be delayed or become infeasible, and commercialization of XDEMVY or marketing approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Until such time as we can generate substantial revenue from product sales, including from XDEMVY, our only approved product, we We expect to finance our cash needs through existing capital balances, revenue from our net product sales, possible combinations of equity offerings, and debt financings, collaborations, strategic alliances and licensing arrangements.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Under this program, the manufacturer is obligated to make its covered drugs available for procurement on an FSS contract and charge a price to the Big Four agencies that is no higher than the Federal Ceiling Price (“FCP”), which is a price calculated pursuant to a statutory formula.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
The Given ongoing discussion with the FDA about our Lyme disease program, they agreed to our proposed approach for a Phase 2b 2 clinical trial, trial of TP-05 which would include several hundred subjects. subjects, with planned trial initiation expected in the second quarter of 2026.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, in In March 2024 2024, we completed a follow-on public offering of approximately 3.3 million shares of our common stock at a public offering price of $32.00 per share and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 shares of our common stock at a price of $31.9999 per pre-funded warrant, for aggregate net proceeds of approximately $107.7 million (after deducting underwriting discounts, commissions and other estimated offering-related expenses) and in 2023 we raised approximately $19.2 million, after deducting broker commissions and fees, through sales under our 2023 ATM Prospectus. expenses).
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
We While we have incurred significant generated revenue from the launch of XDEMVY® (lotilaner ophthalmic solution) 0.25%, we have continued to incur losses and negative cash flows from operations since our inception and anticipate that we could continue to incur significant expenses and potential losses for in the foreseeable future.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
We may not be granted patent term extension either in the U.S. or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our prior losses, combined with expected potential future losses, have had and will could continue to have an adverse effect on our accumulated deficit and working capital.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
It is possible that some ECPs may continue to rely on other treatments for treating symptoms consistent with Demodex blepharitis.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
For example, we have established an internal infrastructure as well as an ECP-focused sales and distribution infrastructure to market XDEMVY and our product candidates in the U.S., and have substantially completed hiring in areas to support commercialization, including sales management, sales representatives, marketing, access and reimbursement, sales support and distribution.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We may need to obtain substantial additional funding to achieve our goals and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, reduce or eliminate our product development programs, commercialization efforts or other operations.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We expect our expenses to continue to increase substantially and we will require a larger amount of capital to fund our commercialization efforts, the development of our product candidates and the maintenance and expansion of our operations and capabilities.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
•Direct-to-consumer (“DTC”) campaign on streaming platforms and network television generated a positive return on investment in 2025 that continues to grow.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
◦Unaided awareness of Demodex blepharitis is now approximately 25% versus 2% of patients surveyed at the beginning of the campaign.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
•We continued to execute on our category-creating strategy, advancing a robust pipeline.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
•Strengthened our leadership with the appointment of David E.I. Pyott, a renowned Biopharmaceutical leader and former Chief Executive Officer and Chairman of Allergan Inc., to the Board of Directors.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
◦Mr. Pyott joined our Board of Directors in February 2026 and brings decades of global leadership experience spanning innovative R&D, product development, and commercial execution. He was instrumental in transforming Allergan from a focused eye care business with approximately $1 billion in revenue into a global specialty pharmaceutical and medical device leader generating more than $7 billion in revenue.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
•Ongoing discussions continue with regulatory authorities in Japan on a potential path to approval of TP-03 for Demodex blepharitis. The Elara prevalence trial showed high prevalence and significant impact of Demodex blepharitis in Japan, consistent with U.S. findings.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
•Our partner in Greater China, GrandPharma, expects potential approval of TP-03 for Demodex blepharitis in 2026.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
Recent global economic conditions have been marked by significant volatility and heightened trade tensions. In addition, persistent inflationary pressures, a prolonged higher interest rate environment, energy supply disruptions in certain regions, evolving trade policies, regulatory uncertainty, and ongoing and emerging geopolitical conflicts, including war, have contributed to regional and global macroeconomic challenges. These conditions have created uncertainty in global markets and may continue to impact economic conditions for an extended period.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
In July 2025, the OBBB Act was enacted in the U.S, which contains a broad range of tax reform provisions affecting businesses, including permitting the immediate expensing of domestic research and development expenditures. Provision for income taxes was $2.1 million for the year ended December 31, 2025, primarily due to state income tax expense resulting from states that do not conform to the OBBB Act and therefore continue to require the capitalization and amortization of domestic research and development expenditures. There was no provision for income taxes recorded during the year ended December 31, 2024.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
which were met. We did not draw on any of the three additional tranches, each of which expired on December 31, 2024, June 30, 2025, and December 31, 2025.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
The following table provides a summary of activity with respect to our sales allowances and accruals for the years ended December 31, 2025 and 2024 (in thousands):
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RemovedMD&A
•We established broad Eye Care Professional ("ECP") utilization across more than 15,000 targets.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
•The expanded sales force deployed in the third quarter 2024 started to deliver meaningfully to the increased ECP utilization and prescription volumes reported for the fourth quarter 2024.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
•Broad commercial, Medicare, and Medicaid reimbursement of XDEMVY now extends to more than 90% of covered lives, as of February 25, 2025.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
•We activated a memorable and action-oriented Direct-to-Consumer ("DTC") campaign on streamlining platforms in the fourth quarter 2024 and initiated a trial-run on network televisions in January 2025, including spots on the Golden Globes, the GRAMMYs and the National Football League playoffs.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
◦The initial patient response from this campaign has been positive across multiple leading indicators, including the downloading of materials, taking the Demodex blepharitis quiz and utilizing the "find an eye doctor tool on the XDEMVY website.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
◦DTC initiatives will continue on streamlining platforms and will meaningfully expand into a network television campaign beginning in the first quarter of 2025.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
TP-03 Demodex blepharitis in patients with Meibomian Gland Disease, Ersa and Rhea Trials
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
We expanded and strengthened our eye care leadership with two key appointments to our executive team and Board of Directors. Elizabeth Yeu, M.D. was appointed Chief Medical Officer in November 2024. Dr. Yeu is a distinguished ophthalmologist with more than two decades of experience who transitioned from her role as our Chief Medical Advisor and a member of our Board of Directors. Katherine H. Goodrich, M.D., MHS was appointed to our Board of Directors in November 2024. Dr. Goodrich is currently the Chief Medical Officer of Humana Inc., and brings decades of experience driving innovative and value-based initiatives designed to improve patient outcomes.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
In Japan, we expect to share results from a Demodex blepharitis prevalence study in the first half of 2025 and meet with Japanese regulatory authorities to help determine a regulatory path forward.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
The Chinese regulatory agency, National Medical Products Administration, accepted the New Drug Application ("NDA") submitted by our partner, Grand Pharmaceutical Group Ltd., for TP-03 for Demodex blepharitis.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
Recently, the economy has experienced downward pressure, and together with high rates of inflation and energy supply issues experienced in certain regions, war and geopolitical conflicts, have led to regional and/or global macroeconomic challenges, the effects of which may be of an extended duration.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
In addition, we may be exposed to credit risk on deposits at financial institutions to the extent our account balances exceed the amount insured by the Federal Deposit Insurance Corporation (“FDIC”). We maintain cash held in deposit at financial institutions in the U.S. While these deposits are insured by the FDIC in an amount up to $250,000 for any depositor, to the extent we hold cash deposits in amounts that exceed the FDIC insurance limitation, we may incur a loss in the event of a failure of any of the financial institutions where we maintain deposits. We invest our excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty. We believe the Company is not exposed to significant credit risk due to the financial position of the depository institutions and the types of accounts we hold, but we will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RewordedMD&A
To date date, we have financed our operations through private placements of preferred stock, convertible promissory notes, net proceeds from issuance of common stock in our Initial Public Offering ("IPO"), initial public offering (“IPO”), our subsequent follow-on public offerings in May 2022 (the "May “May 2022 Public Offering"), Offering”), August 2023 (the "August “August 2023 Public Offering"), and Offering”), March 2024 (the "March “March 2024 Public Offering", Offering”), and March 2025 (the “March 2025 Public Offering”, collectively the "Follow-On “Follow-On Public Offerings"), Offerings”), and our Open Market Sale AgreementTM (the "2023 “2023 ATM Prospectus"), Prospectus”), as well as proceeds from net product sales, our China Out-License, and drawdowns from the loan and security agreement (the “2024 Credit Facilities. Facility”) with funds associated with Pharmakon Advisors, LP (“Pharmakon”), and the previous loan and security agreement with Hercules Capital, Inc. and Silicon Valley Bank, a division of First Citizens Bank & Trust Company (the “2022 Credit Facility”, and collectively the “Credit Facilities”).
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by financing activities was $130.2 $143.4 million for the year ended December 31, 2023, 2025, and consisted of (i) $99.4 $134.8 million of net proceeds from the issuance of common stock from our August 2023 March 2025 Public Offering, (ii) $19.2 $6.3 million of net proceeds from common employee stock sold under the 2023 ATM Prospectus, option exercises, and (iii) $10.0 $2.3 million of proceeds from our 2022 Credit Facility, (iv) $1.0 million of proceeds from our ESPP, and (v) $0.6 million of proceeds from the exercise of vested employee stock options. Employee Stock Purchase Plan (“ESPP”).
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
The increase was primarily due to (i) $3.5 $8.9 million of increased indirect expenses related to payroll and personnel-related costs (including increased stock-based compensation expense of $1.0 $3.2 million) for employee additions to drive our product development initiatives, (ii) $0.7 $1.6 million of increased other indirect expenses, (iii) a $1.5 million increase in milestone expense related to our in-license agreements (see Note 9), and (iv) $1.2 $3.3 million of increased TP-03 early-stage programs, and (iv) $2.4 million of increased TP-04 program expenses.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
See the section titled "Risk Factors" for a further discussion of For additional information regarding the potential adverse impact effects of unfavorable global and geopolitical economic conditions on our business, results of operations and financial condition. condition, please see “Risk Factors” in Item 1A of Part I of this Annual Report on Form 10-K.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
The Given ongoing discussions with the FDA about our Lyme disease program, they agreed to our proposed approach for a Phase 2b 2 clinical trial, trial of TP-05 (an investigational oral tablet), which would include several hundred subjects. subjects with planned trial initiation expected in the second quarter of 2026.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
The AAOpt presentation, presentations, which combined the Ersa and Rhea trials Trials data in a pooled analysis, demonstrated that XDEMVY provided statistically significant and clinically meaningful improvements of the meibomian glands from baseline and when compared to vehicle. vehicle, including at least three times more glands secreting normal or clear liquid in patients treated with XDEMVY compared to vehicle at day 43.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
The 2024 Public Offering was In March 2025, we completed an underwritten follow-on public offering under the 2024 Shelf Registration Statement, Statement pursuant to which we sold 2,812,500 shares of our common stock, and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 2,808,988 shares of our common stock.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
We have also completed, and/or have ongoing completed clinical trials for the potential treatment of in Demodex blepharitis in patients with Meibomian Gland Disease ("MGD"), (“MGD”), including the Ersa Phase 2a clinical trial involving XDEMVY, (the “Ersa Trial”), and the Rhea a pilot clinical trial (the “Rhea Trial”) involving an XDEMVY vehicle; vehicle.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
In January December 2025, we announced plans to initiate initiated a Phase 2 study in the second half of 2025 trial for the potential treatment of Ocular Rosacea. ocular rosacea with topline results expected in the first half of 2027.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
We expect to While we have generated revenue from the launch of XDEMVY, we could incur significant operating losses for in the foreseeable future, and for these losses to further increase, future as we expand our clinical development programs for our other product candidates and continue to commercialize XDEMVY.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
After review of this the Galatea trial data with the FDA and Key Opinion Leaders, key opinion leaders (“KOLs”), we decided to pursue development of TP-04 for the potential treatment for Ocular Rosacea. ocular rosacea, a highly prevalent and underserved eye disease with no FDA-approved therapy.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Until such time as we can generate significant revenue from product sales and achieve profitability, if ever, we We expect to finance our operations through existing capital balances, revenue from product sales, public equity or debt financings, or collaborations, strategic alliances, or licensing arrangements with third parties.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new